Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs FTAI Aviation Ltd (FTAI) Price & Performance

Abeona Therapeutics IncTrade
FTAI Aviation LtdTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs FTAI Aviation Ltd — how do they compare? Abeona Therapeutics Inc trades at $7.39 (market cap $421.19M), while FTAI Aviation Ltd trades at $228.72 (market cap $23.17B). The key difference: FTAI Aviation Ltd is far larger — about 55× Abeona Therapeutics Inc's market cap, and FTAI Aviation Ltd pays a 0.89% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOFTAI
Market Cap
$421.19M$23.17B
Sector
HealthIndustrials
52-Week High
$7.45$310.04
52-Week Low
$4.17$140.40
Enterprise Value
$276.10M$26.29B
Dividend Yield
0.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

FTAI Aviation Ltd

FTAI Aviation trades at $229.92, up 6.94% today, with a neutral technical signal and bearish moving averages. Recent earnings missed expectations for three consecutive quarters, though revenue grew to $2.51B in 2025. The company announced a strategic investor relations transition and a significant $1.465B turbine order, signaling operational momentum. Valuation ratios remain elevated, with a P/E of 49.26 and P/B of 57.36, reflecting high growth expectations.

The outlook is mixed: strong analyst consensus (100% buy ratings, $341.67 target) and institutional accumulation support upside, but earnings misses and declining net margins pose risks. Key opportunities include power segment growth and data center demand, while execution on guidance and profitability trends are critical watchpoints for investors.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About FTAI Aviation Ltd

FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.

Read more on FTAI